Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine

Journal of Immunotherapy

Volumn 27, Issue 5, 2004, Pages 368-379

  Chiong, Brian ^a   Wong, Raymond ^a   Lee, Peter ^b   Delto, Joan ^a   Scotland, Ronald ^a   Lau, Roy ^a   Weber, Jeffrey ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antigen specific; ELISPOT; gp100; Immunotherapy; Tetramers

Indexed keywords

CD28 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHROMIUM; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; HLA A ANTIGEN; INTERLEUKIN 12; MELANOMA VACCINE; MONTANIDE ISA 51; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; MELANOMA; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 4344614603     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200409000-00005     Document Type: Article

References (49)

1. Mercado R. Early programming of T cell populations responding to bacterial infection. J Immunol. 2000;165:6833-6839.
2. + T cell differentiation: initial antigen encounter triggers a differentiation program in naïve cells. Nat Immunol. 2001;2:415-422.
3. Sallustro F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1998;410:708-712.
4. Lanzavecchie A, Sallustro F. Antigen decoding by T lymphocytes: from synapse to fate determination. Nat Immunol. 2001;2:487-492.
5. Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J. 2000;3(suppl):S200-S207.
6. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-269.
7. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
8. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997;3:37-44.
9. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with Incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
10. Pittet MJ, Speiser DE, Lienard D, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res. 2001;7(suppl):796s-803s.
11. Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T cell response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 2001;98:10290-10295.
12. Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome. Clin Cancer Res. 2001;7: 3012-3024.
13. Nielsen MB, Monsurro V, Migueles SA, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol. 2000;165:2287-2296.
14. Stewart JH 4th, Rosenberg SA. Long term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine. J Immunother. 2000;23:401-404.
15. Altman J, Moss PAH, Goulder P, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science. 1998;274:94-96.
16. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma. J Clin Oncol. 2001;19:3836-3847.
17. Weber J, Sondak V, Scotland R, et al. Granulocyte-macrophage colony stimulating factor added to a multi-peptide vaccine for resected stage II melanoma. Cancer. 2003;97:186-200.
18. Rubio V, Stuge T, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377-1382.
19. Bakker ABH, Schreurs WJ, de Boer AJ, et al. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179:1005-1011.
20. Bakker ABH, Schreurs MWJ, Tafazzul G, et al. Identification of a novel peptide derived from the melanocyte specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int J Cancer. 1995;62:97-102.
21. Kawakami Y, Eliyahu S, Delgado C, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458-6462.
22. Jager E, Maeurer M, Hohn H, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer. 2000;86: 538-547.
23. Scheibenbogen C, Nagorsen D, Seliger B, et al. Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer. 2002;99:403-408.
24. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol. 1996;157:2536-2548.
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
26. Lally KM, Mocellin S, Ohnmacht GA, et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer. 2001;93:841-847.
27. Valmori D, Dutoit V, Schnuriger V, et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol. 2002;168:4231.
28. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99:23-33.
29. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286:2098-2102.
30. Sallustro F, Lanazavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401: 708-712.
31. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2: 251-262.
32. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 2003;4:225-234.
33. Hoon DSB, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109-2116.
34. Palmieri G, Strazullo M, Ascierto PA, et al. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol. 1999;17:304-311.
35. Valmori D, Scheibenbogen C, Nagorsen D, et al. Circulation tumor-reactive CD8(-) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 2002;62:1743-1750.
36. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor specific cytolytic T lymphocytes. J Exp Med. 1998;188:1641-1650.
37. Nielsen MB, Monsurro V, Migueles SA, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol. 2000;165:2287-2296.
38. Lee KH, Wang E, Nielsen MB, et al. Inreased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292-6300.
39. Monsurro V, Nielsen MB, Perez-Diez A, et al. Kinetics of TCR use in response to repeated epitope-specific immunizations. J Immunol. 2001; 166:5817-5825.
40. Scheibenbogen C, Nagorsen D, Seliger B, et al. Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer. 2002;99:403-408.
41. Jager E, Maeurer M, Hohn H, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer. 2000;86: 538.
42. Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 1996;67:54-62.
43. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230.
44. Saleh FH, Crotty KA, Hersey P, et al. Primary melanoma tumor regression associated with an immune response to the tumor associated antigen melan-A/MART-1. Int J Cancer. 2001;94:551-557.
45. Grayson JM, Zajac AJ, Altman JD, et al. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J Immunol. 2000; 164:3950-3954.
46. Wan J, Martinvalet D, Ji X, et al. The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes. Immunology. 2003;110:10-17.
47. Monsurro V, Nagorsen D, Wang E, et al. Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol. 2002;168:5933-5942.
48. Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogenous CTL response. J Immunother. 1999;22:288-298.
49. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.